298 related articles for article (PubMed ID: 20670140)
21. Nuclear Brachyury Expression Is Consistent in Chordoma, Common in Germ Cell Tumors and Small Cell Carcinomas, and Rare in Other Carcinomas and Sarcomas: An Immunohistochemical Study of 5229 Cases.
Miettinen M; Wang Z; Lasota J; Heery C; Schlom J; Palena C
Am J Surg Pathol; 2015 Oct; 39(10):1305-12. PubMed ID: 26099010
[TBL] [Abstract][Full Text] [Related]
22. From notochord formation to hereditary chordoma: the many roles of Brachyury.
Nibu Y; José-Edwards DS; Di Gregorio A
Biomed Res Int; 2013; 2013():826435. PubMed ID: 23662285
[TBL] [Abstract][Full Text] [Related]
23. Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas.
Shalaby AA; Presneau N; Idowu BD; Thompson L; Briggs TR; Tirabosco R; Diss TC; Flanagan AM
Mod Pathol; 2009 Aug; 22(8):996-1005. PubMed ID: 19407855
[TBL] [Abstract][Full Text] [Related]
24. Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target.
Hsu W; Mohyeldin A; Shah SR; ap Rhys CM; Johnson LF; Sedora-Roman NI; Kosztowski TA; Awad OA; McCarthy EF; Loeb DM; Wolinsky JP; Gokaslan ZL; Quiñones-Hinojosa A
J Neurosurg; 2011 Oct; 115(4):760-9. PubMed ID: 21699479
[TBL] [Abstract][Full Text] [Related]
25. Distinguishing chordoid meningiomas from their histologic mimics: an immunohistochemical evaluation.
Sangoi AR; Dulai MS; Beck AH; Brat DJ; Vogel H
Am J Surg Pathol; 2009 May; 33(5):669-81. PubMed ID: 19194275
[TBL] [Abstract][Full Text] [Related]
26. Targeted brachyury degradation disrupts a highly specific autoregulatory program controlling chordoma cell identity.
Sheppard HE; Dall'Agnese A; Park WD; Shamim MH; Dubrulle J; Johnson HL; Stossi F; Cogswell P; Sommer J; Levy J; Sharifnia T; Wawer MJ; Nabet B; Gray NS; Clemons PA; Schreiber SL; Workman P; Young RA; Lin CY
Cell Rep Med; 2021 Jan; 2(1):100188. PubMed ID: 33521702
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of VEGF receptors expression on the tumor cells in skull base chordoma.
Morimoto Y; Tamura R; Ohara K; Kosugi K; Oishi Y; Kuranari Y; Yoshida K; Toda M
J Neurooncol; 2019 Aug; 144(1):65-77. PubMed ID: 31240525
[TBL] [Abstract][Full Text] [Related]
28. A Diagnostic Pitfall: Atypical Teratoid Rhabdoid Tumor Versus Dedifferentiated/Poorly Differentiated Chordoma: Analysis of a Mono-institutional Series.
Buccoliero AM; Caporalini C; Scagnet M; Baroni G; Moscardi S; Mussa F; Giordano F; Sardi I; Genitori L
Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):147-154. PubMed ID: 28777153
[TBL] [Abstract][Full Text] [Related]
29. Histological study of chordoma origin from fetal notochordal cell rests.
Shen J; Shi Q; Lu J; Wang DL; Zou TM; Yang HL; Zhu GQ
Spine (Phila Pa 1976); 2013 Dec; 38(25):2165-70. PubMed ID: 24296480
[TBL] [Abstract][Full Text] [Related]
30. Emerging Therapeutic Targets in Chordomas: A Review of the Literature in the Genomic Era.
Gill CM; Fowkes M; Shrivastava RK
Neurosurgery; 2020 Feb; 86(2):E118-E123. PubMed ID: 31504814
[TBL] [Abstract][Full Text] [Related]
31. Chondroid chordoma--a variant of chordoma. A morphologic and immunohistochemical study.
Rosenberg AE; Brown GA; Bhan AK; Lee JM
Am J Clin Pathol; 1994 Jan; 101(1):36-41. PubMed ID: 7506477
[TBL] [Abstract][Full Text] [Related]
32. Clinicocytopathological spectrum, including uncommon forms, of nine cases of chordomas with immunohistochemical results, including brachyury immunostaining: A single institutional experience.
Rekhi B; Karmarkar S
Cytopathology; 2019 Mar; 30(2):229-235. PubMed ID: 30218622
[TBL] [Abstract][Full Text] [Related]
33. Chondroid chordomas and low-grade chondrosarcomas of the craniospinal axis. An immunohistochemical analysis of 17 cases.
Wojno KJ; Hruban RH; Garin-Chesa P; Huvos AG
Am J Surg Pathol; 1992 Dec; 16(12):1144-52. PubMed ID: 1463093
[TBL] [Abstract][Full Text] [Related]
34. Malignant tumors with clear cell morphology: a comparative immunohistochemical study with renal cell carcinoma antibody, Pax8, steroidogenic factor 1, and brachyury.
Clayton EF; Ziober A; Yao Y; Bing Z
Ann Diagn Pathol; 2013 Apr; 17(2):192-7. PubMed ID: 23218904
[TBL] [Abstract][Full Text] [Related]
35. Non-rhabdoid pediatric SMARCB1-deficient tumors: overlap between chordomas and malignant rhabdoid tumors?
Renard C; Pissaloux D; Decouvelaere AV; Bourdeaut F; Ranchère D
Cancer Genet; 2014 Sep; 207(9):384-9. PubMed ID: 25053104
[TBL] [Abstract][Full Text] [Related]
36. [A clinicopathological and immunohistochemical study of 34 cases of chordoma].
Hu Y; Gao Y; Zhang X
Zhonghua Bing Li Xue Za Zhi; 1996 Jun; 25(3):142-4. PubMed ID: 9275666
[TBL] [Abstract][Full Text] [Related]
37. Primary, large extra-axial chordoma in proximal tibia: a rare case report with literature review and diagnostic implications.
Rekhi B
APMIS; 2016 Mar; 124(3):238-42. PubMed ID: 26522887
[TBL] [Abstract][Full Text] [Related]
38. Dedifferentiated Chordoma: Clinicopathologic and Molecular Characteristics With Integrative Analysis.
Hung YP; Diaz-Perez JA; Cote GM; Wejde J; Schwab JH; Nardi V; Chebib IA; Deshpande V; Selig MK; Bredella MA; Rosenberg AE; Nielsen GP
Am J Surg Pathol; 2020 Sep; 44(9):1213-1223. PubMed ID: 32427623
[TBL] [Abstract][Full Text] [Related]
39. D2-40 functions as an effective chondroid marker distinguishing true chondroid tumors from chordoma.
Huse JT; Pasha TL; Zhang PJ
Acta Neuropathol; 2007 Jan; 113(1):87-94. PubMed ID: 17021752
[TBL] [Abstract][Full Text] [Related]
40. [Notochordal tumors : Benign notochordal tumors and chordomas].
Barth TFE; von Witzleben A; Möller P; Scheil-Bertram S
Pathologe; 2018 Mar; 39(2):117-124. PubMed ID: 29236139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
